One Innovative Pharmaceutical Biotech Insider Raised Stake By 15% In Previous Year

Looking at Innovative Pharmaceutical Biotech Limited's (HKG:399 ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Innovative Pharmaceutical Biotech

The Last 12 Months Of Insider Transactions At Innovative Pharmaceutical Biotech

In the last twelve months, the biggest single purchase by an insider was when insider Yiu Ting Chau bought HK$11m worth of shares at a price of HK$0.22 per share. So it's clear an insider wanted to buy, at around the current price, which is HK$0.23. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Innovative Pharmaceutical Biotech insider decided to buy shares at close to current prices. Yiu Ting Chau was the only individual insider to buy shares in the last twelve months.

Yiu Ting Chau bought 100.00m shares over the last 12 months at an average price of HK$0.21. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Innovative Pharmaceutical Biotech is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Innovative Pharmaceutical Biotech insiders own about HK$201m worth of shares (which is 49% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Does This Data Suggest About Innovative Pharmaceutical Biotech Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. It would be great to see more insider buying, but overall it seems like Innovative Pharmaceutical Biotech insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Our analysis shows 6 warning signs for Innovative Pharmaceutical Biotech (2 are a bit unpleasant!) and we strongly recommend you look at these before investing.

Of course Innovative Pharmaceutical Biotech may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.